Medicare Just Gave the Green Light to a Blood Test for MASH. Here's Why That's a Big Deal.
Medicare has approved reimbursement for NASHnext®, a non-invasive blood test for at-risk MASH patients. This milestone could reshape diagnostics and unlock a massive market—and it's a perfect example of tech scaling where it's needed most.
Let's be real: the healthcare system is notoriously slow to adopt new tech. But every once in a while, a signal cuts through the noise. This week, that signal came from Medicare.
On August 10, 2026, Medicare will start reimbursing NASHnext®—a non-invasive blood test developed by Labcorp and powered by GENFIT's NIS4® technology—at roughly $252 per test. This isn't just a win for a single company. It's a massive unlock for an entire diagnostic category.
We're talking about a test that identifies patients with at-risk MASH (metabolic dysfunction-associated steatohepatitis). Think of it as an early warning system for a disease that's been flying under the radar for years. And now, with reimbursement locked in, the path to scale is wide open.
The Diagnostic Gap Is Real
Here's the stat that should make you sit up: projections show that by 2030, nearly 260 million U.S. adults will have risk factors for metabolic disease. Of those, around 90 million will have elevated liver enzymes or steatosis. That's a massive population walking around with a ticking clock on their liver health, and most of them have no idea.
Until now, the standard of care has been either a liver biopsy (painful, invasive, expensive) or waiting until symptoms get bad enough to warrant imaging. Neither is scalable. Neither is proactive.
NASHnext® changes that. It captures both disease activity and fibrotic burden, including F2 fibrosis. That's the sweet spot—catching patients before they progress to cirrhosis or liver failure. As Dr. Naim Alkhouri put it:
"Securing Medicare coverage is a critical step toward integrating non-invasive blood-based testing into routine clinical practice. In MASH, many patients already within the disease spectrum remain unidentified until they have progressed to more advanced stages."
This is exactly the kind of tech-forward thinking that makes me optimistic. We're finally moving from reactive to predictive medicine.
Why This Matters for the Market
The timing is perfect. The first MASH therapy just hit near-blockbuster status in its first year. More drugs are coming from big pharma players. But here's the thing: you can't treat what you can't find.
Diagnostics are the bottleneck. And Medicare just removed a major logjam.
With reimbursement in place, private insurers will likely follow. That means more doctors ordering the test, more patients getting diagnosed earlier, and more opportunities for pharma to connect with the right patients. It's a flywheel effect.
GENFIT is positioned to establish a second revenue stream through its licensing deal with Labcorp. Expect more guidance in the fall. But the writing is on the wall: non-invasive diagnostics are the future.
What This Reminds Me Of
This whole situation feels familiar. In tech, we talk about "scaling" all the time. But scaling a software product is easy compared to scaling a diagnostic test through a fragmented healthcare system. The barriers are regulatory, financial, and behavioral.
Yet here we are. A blood test that takes minutes, costs a fraction of a biopsy, and gives clinicians actionable data? That's disruption. Real disruption.
And it's not just in healthcare. Every industry is being reshaped by tools that remove friction. Take expense reporting, for example. For years, people have been manually tracking receipts, filling out spreadsheets, and chasing down approvals. It's a pain. It's slow. And it costs you money.
That's why I'm excited about products like ccLuca. Snap a photo, get AI-extracted data in 3 seconds, generate expense reports instantly. No IT. No enterprise software. Just you and your expenses, sorted. The same principle applies: remove the friction, and you unlock value.
The Bottom Line
Medicare's decision on NASHnext® is a signal. It says: non-invasive, scalable diagnostics are ready for prime time. The technology works. The economics work. And the clinical need is undeniable.
For GENFIT and Labcorp, this is a major milestone. For patients, it's a chance to catch a silent disease before it's too late. And for anyone watching the intersection of tech and healthcare, it's a reminder that the best innovations are the ones that just work—without a fuss.
Now, if only we could get that same efficiency into expense reports. Oh wait, we can.